CGMs for Non-Diabetics: A Complete Guide to Metabolic Health Tracking

Continuous glucose monitors (CGMs) allow real-time tracking of blood glucose levels without finger-stick testing. For healthy non-diabetic adults, CGM use offers insight into individual glycaemic responses to foods, exercise, stress, and sleep. Human studies suggest that glucose variability — not just average levels — is associated with metabolic and cardiometabolic health markers. CGMs are increasingly accessible over the counter in some markets, making them a practical self-monitoring tool for longevity-focused individuals.

Key Takeaways

  • Glucose variability — how much blood sugar fluctuates throughout the day — may be a more informative marker of metabolic health than average glucose alone, based on observational data from human cohort studies.1
  • A 2024 systematic review and meta-analysis found that, in non-diabetic individuals, higher glucose variability was associated with coronary atherosclerosis development and may help predict cardiometabolic risk, though causality has not been established.2
  • CGMs measure interstitial fluid glucose rather than blood glucose directly, introducing a physiological lag of approximately 5–15 minutes; this is a known and manageable limitation, particularly during rapid glucose changes.3
  • Consumer CGM platforms such as Levels, Nutrisense, and Dexcom Stelo differ in sensor hardware, coaching model, subscription structure, and over-the-counter (OTC) availability — each serving different user needs.
  • Chromium contributes to normal macronutrient metabolism and maintenance of normal blood glucose levels (EFSA-approved claim), and magnesium has been studied in relation to insulin sensitivity in human trials — both are nutrients relevant in the context of metabolic health support.5,6
  • A short CGM period of 2–4 weeks can reveal consistent individual patterns in postprandial glucose, sleep-related glucose changes, and exercise responses that no single blood test could capture.
  • CGM data is a tool for informed self-monitoring, not a diagnostic substitute for clinical evaluation. Individuals with health concerns should consult a qualified healthcare professional.

What Is Glucose Variability and Why Does It Matter?

When most people think about blood sugar, they think of a single number — a fasting glucose result or an HbA1c value taken at a clinic visit. These are useful snapshots, but they tell a limited story. Blood glucose moves continuously throughout the day, rising after meals, dipping during fasting periods, responding to stress, shifting with exercise, and changing during sleep. The degree to which glucose fluctuates — known as glucose variability — is increasingly recognised as a distinct aspect of metabolic health.

Two common metrics are used to describe variability. Time in range (TIR) refers to the percentage of time glucose remains within a defined target window, typically 3.9–7.8 mmol/L (70–140 mg/dL) according to American Diabetes Association secondary targets, or a stricter range of 3.9–5.6 mmol/L for metabolically healthy individuals. The coefficient of variation (CV%) reflects the standard deviation of glucose divided by the mean, expressing day-to-day fluctuation as a percentage. A lower CV% generally indicates more stable glucose dynamics.

A large observational study of 4,135 participants without diabetes from the PREDICT cohort programme found that CGM-derived variability metrics were associated with markers of cardiometabolic health, including HOMA-IR (a marker of insulin resistance) and 10-year cardiovascular risk scores. Crucially, the stricter time-in-range target of 3.9–5.6 mmol/L was more sensitive for detecting these differences than the standard ADA range — suggesting that meaningful metabolic variation may exist even within what is conventionally considered "normal" glucose.1

A subsequent 2024 systematic review and meta-analysis specifically examining CGM-derived glycaemic variability in non-diabetic individuals concluded that glucose variability is elevated in prediabetes relative to normoglycaemia, and found associations between higher variability and coronary atherosclerosis development. The reviewers noted that causal relationships are difficult to establish from observational data, and that heterogeneity across included studies limits definitive conclusions — an important transparency note for anyone interpreting CGM data in a non-clinical context.2

Earlier human research found that glycaemic variability was associated with elevated interleukin-6 (a pro-inflammatory cytokine) and lower adiponectin (an anti-inflammatory marker) in non-diabetic subjects with metabolic syndrome, compared with subjects without metabolic syndrome. These findings suggest a potential relationship between glucose fluctuations and systemic inflammatory tone even before overt diabetes develops.4

Additionally, a human study examining glycaemic variability and endothelial function reported that variability influenced endothelial function even in non-diabetic participants, suggesting a possible pathway linking glucose dynamics to vascular health that extends beyond diabetic populations.7

It is worth noting that glucose variability research remains an evolving field. The studies cited above are largely observational and cross-sectional; they describe associations rather than cause-and-effect relationships. Whether reducing glucose variability through dietary or lifestyle interventions meaningfully improves long-term health outcomes in non-diabetic adults has not been established in large, long-term randomised controlled trials. Interpreting personal CGM data should be done with this limitation in mind.

How CGMs Work and What They Measure

A CGM device consists of a small electrode inserted just beneath the skin, typically on the upper arm or abdomen. Rather than measuring glucose in the blood directly, CGMs measure glucose in the interstitial fluid — the fluid that surrounds cells in the subcutaneous tissue. Glucose moves from blood into the interstitial compartment by diffusion, meaning CGM readings are an indirect estimate of blood glucose.

This biochemical pathway introduces a physiological time lag. A direct measurement study in healthy fasted adults estimated the physiological delay of glucose transport from the vascular to the interstitial space at approximately 5–6 minutes under fasting conditions. However, during periods of rapidly changing glucose — such as after a meal or during intense exercise — the lag between blood and interstitial glucose can extend meaningfully, and sensor algorithms add additional processing time. In clinical studies, the combined lag between actual blood glucose and CGM readings has been reported to range from approximately 5 to 21 minutes depending on the device and physiological conditions.3

The practical implication is that CGM values may trail blood glucose by several minutes during rapid changes. For a non-diabetic tracking lifestyle responses rather than making insulin dosing decisions, this lag is generally not clinically significant. However, it is relevant context for interpreting postprandial peaks and activity-related drops. A CGM reading taken immediately after a high-carbohydrate meal, for example, may not yet reflect the full postprandial response.

Modern CGMs update glucose readings every 1–15 minutes and display trend arrows indicating whether glucose is stable, rising, or falling. Most consumer-facing devices are factory-calibrated and do not require finger-stick blood glucose calibration, simplifying use for non-diabetic individuals. Typical wear periods range from 10 to 15 days per sensor before replacement. Current-generation devices include the Abbott Freestyle Libre series, Dexcom G-series, and Stelo (Dexcom's OTC device), as well as integrations offered by platforms such as Nutrisense and Levels.

Nutrisense vs Levels vs Dexcom Stelo: Platform Comparison

The consumer CGM market for non-diabetics has matured considerably, with several platforms now offering structured programmes built around the same core sensor hardware. Understanding how these platforms differ helps individuals select the option that best matches their goals, budget, and preferred level of support.

Levels Health pairs CGMs (typically Abbott Freestyle Libre or Dexcom sensors) with a proprietary mobile application that scores meals and activities based on glucose response, and provides educational feedback. Levels operates on a subscription model and has historically offered flat commission affiliate partnerships. The platform emphasises metabolic optimisation and appeals to a health-focused audience comfortable with quantified self-monitoring. Coaching support has been available as an optional add-on.

Nutrisense offers a similar CGM-plus-app model but places greater emphasis on registered dietitian coaching as a core feature. Users receive ongoing dietary consultation alongside their glucose data, which distinguishes it from purely self-directed platforms. This model suits users who want professional interpretation rather than autonomous data analysis. Pricing is comparable to Levels, with monthly subscription tiers that include sensor costs.

Dexcom Stelo represents a different access model: it is an OTC CGM cleared by the FDA for use without a prescription, making it the most accessible option by regulatory pathway in the United States for adults without diabetes. Stelo uses the Dexcom sensor platform and provides a standalone mobile app with basic glucose data display. It does not include coaching or structured programming, positioning it as a lower-cost, lower-support entry point. Stelo is notable because it marks a regulatory shift toward CGM availability for the general adult population.

Abbott Freestyle Libre remains available by prescription in many markets and is the sensor of choice for several third-party platforms. In some European markets, it is available over the counter. The Libre Pro is a professional-grade blinded sensor used in clinical and research settings.

A comparison across key dimensions:

  • Sensor brand used: Levels and Nutrisense typically use Abbott Freestyle Libre or Dexcom G7; Stelo uses dedicated Dexcom hardware.
  • Coaching model: Nutrisense includes dietitian coaching; Levels focuses on app-based algorithmic feedback; Stelo provides no coaching.
  • OTC access: Dexcom Stelo is OTC in the US; other platforms typically require online health screening or subscription signup rather than a formal prescription, though regulatory pathways vary by market.
  • Price range: Approximately $100–$200 per month including sensors and platform access for Levels and Nutrisense; Stelo sensors are lower cost when purchased directly.
  • Best-for profile: Stelo suits individuals who want basic self-monitoring data at lower cost; Nutrisense suits those who want expert dietary guidance; Levels suits individuals comfortable with independent data interpretation and detailed metabolic scoring.

None of these platforms are intended to diagnose, treat, or manage medical conditions. Their value in non-diabetic individuals lies in observational insight — helping users understand how their lifestyle choices interact with their glucose dynamics.

What a CGM Teaches You About Your Metabolism

A 2–4 week CGM period in a non-diabetic adult typically reveals patterns that no standard blood panel could capture. Understanding what to look for — and how to interpret the data with appropriate context — is central to using CGM meaningfully.

Individual food responses: One of the most consistent findings in non-diabetic CGM research is that postprandial glucose responses vary substantially between individuals eating identical meals. The PREDICT 1 study, a large human intervention study tracking both clinical measurements and free-living CGM data, found that identical dietary challenges produced highly variable glycaemic responses across participants, associated with differences in microbiome composition, body composition, lifestyle, and meal timing.1 This individual variability means that population-level glycaemic index data for foods may not accurately predict a given person's postprandial response.

Exercise effects on glucose: Aerobic exercise typically produces an initial glucose dip during activity, followed by a period of improved insulin sensitivity. Resistance training responses can vary more, sometimes showing a transient rise due to stress hormone activation before glucose normalises. A CGM makes these dynamics visible in real time, allowing individuals to observe how different types, durations, and timings of exercise affect their glucose patterns over multiple sessions.

Sleep and glucose: Glucose is not static during sleep. Many people observe a characteristic overnight rise (the Dawn Phenomenon) driven by cortisol and growth hormone activity in the early morning hours, which can elevate fasting glucose readings. Poor sleep quality has been associated with elevated postprandial glucose the following day, though isolating sleep as a causal variable in real-world CGM data is methodologically challenging.

Fasting windows: Individuals practising intermittent fasting often use CGM data to observe how different fasting durations affect their baseline glucose and fasting insulin dynamics over time. Pairing CGM data with a fasting protocol (explored in more detail in our intermittent fasting guide) can help individuals identify personal sweet spots for meal timing.

Stress responses: Cortisol, released in response to acute stress, stimulates hepatic glucose production. Some CGM users observe meaningful glucose elevations during stressful meetings, travel, or poor sleep periods that have no dietary explanation — making the stress-glucose connection more personally concrete.

Setting realistic expectations is important. A CGM provides observational data, not clinical guidance. Transient glucose spikes after specific foods are not equivalent to a diagnosis of dysregulated glucose metabolism. Responses vary day-to-day depending on sleep, stress, prior exercise, and food sequencing. Using a CGM is most valuable when patterns — not individual data points — are the focus of interpretation, ideally over 2–4 weeks of consistent wear.

Chromium, Magnesium, and Metabolic Support: The Supplement Context

For individuals using a CGM alongside a broader health optimisation approach, two micronutrients — chromium and magnesium — are frequently discussed in the context of metabolic health. Their inclusion here follows regulatory and scientific frameworks rather than therapeutic claims.

Chromium and blood glucose metabolism: Chromium (as trivalent chromium, Cr(III)) is an essential micronutrient involved in macronutrient metabolism. The European Food Safety Authority (EFSA) has approved the following health claim: chromium contributes to normal macronutrient metabolism and maintenance of normal blood glucose levels. This is a nutrient function claim, not a therapeutic claim. It indicates that adequate chromium intake plays a role in normal physiological processes.

In terms of supplementation evidence, a meta-analysis of randomised controlled trials in individuals with type 2 diabetes found significant reductions in fasting glucose, HbA1c, and HOMA-IR with chromium supplementation compared to placebo.8 However, an earlier meta-analysis evaluating chromium in non-diabetic participants specifically found no statistically significant association between chromium supplementation and glucose or insulin concentrations in non-diabetic subjects — a finding that highlights the importance of population context when interpreting supplement evidence.9 Chromium supplementation should be understood as supporting adequate nutrient status rather than as a glucose-lowering intervention.

Magnesium and insulin sensitivity: Magnesium is involved in over 300 enzymatic processes, including those related to glucose transport, glycolysis, and insulin receptor signalling. EFSA-approved claims for magnesium include that it contributes to normal energy-yielding metabolism and normal protein synthesis — functional roles relevant to metabolic health.

A systematic review and meta-analysis evaluating RCTs of oral magnesium supplementation in both diabetic and non-diabetic individuals found a significant effect on HOMA-IR (a marker of insulin resistance), with a weighted mean difference of -0.67 (95% CI: -1.20 to -0.14) compared to placebo, suggesting that magnesium supplementation may support insulin sensitivity — particularly in individuals with lower baseline magnesium status.5 A double-blind, placebo-controlled RCT specifically in non-diabetic subjects with insulin resistance found that oral magnesium supplementation reduced HOMA-IR values compared to placebo, supporting the relevance of magnesium adequacy even outside a diabetic context.6

A separate systematic review of RCTs examining the effect of magnesium supplementation on insulin resistance concluded that supplementation reduced HOMA-IR values in seven of twelve eligible studies and influenced fasting glucose in eight of twelve — with effects most consistent in individuals presenting with low baseline magnesium.10

These findings frame chromium and magnesium as nutrients that play functional roles in metabolic processes — relevant context for individuals who use CGM data to optimise their metabolic health. Supplementation should be considered in the context of overall dietary sufficiency, lifestyle, and individual health status, and is not a substitute for the dietary and lifestyle fundamentals that CGM data can help individuals refine.

Q&A: CGM Use for Non-Diabetics

Q1: Can a non-diabetic person benefit from wearing a CGM?

Yes, potentially — though the nature of the benefit differs from a clinical diabetes management context. For a metabolically healthy non-diabetic adult, a CGM provides observational data about how individual foods, exercise, sleep, and stress interact with their glucose dynamics.1 This information may help guide personalised dietary and lifestyle choices, though whether acting on this data improves long-term health outcomes in non-diabetics has not been established in clinical trials. The CGM itself does not change glucose — it informs behaviour.

Q2: Is glucose variability the same thing as high blood sugar?

No. Glucose variability refers to how much glucose fluctuates over time, independent of the average level. A person can have a normal average glucose but high variability — characterised by repeated spikes and drops — or a low average glucose with minimal variability. Research suggests these are distinct phenomena with potentially different implications for metabolic health, though the evidence in non-diabetic populations is still developing.2

Q3: Why does a CGM reading sometimes differ from a finger-stick glucose test?

CGMs measure glucose in interstitial fluid, not blood. Because glucose moves from blood into the interstitial space by diffusion, there is a physiological lag — typically 5–15 minutes — between blood glucose and CGM readings. During periods of rapid glucose change (post-meal, during exercise), this discrepancy is most pronounced.3 For most non-diabetic use cases, this lag is not clinically meaningful, but it is worth understanding when interpreting sharp glucose peaks or drops.

Q4: How long should a non-diabetic wear a CGM to learn something useful?

Most CGM programmes for non-diabetics recommend a minimum of 2 weeks, with 4 weeks considered more informative. A single week may not capture enough day-to-day variation to identify reliable patterns. Wearing the sensor across different circumstances — weekdays vs. weekends, training days vs. rest days, varying meal types — increases the educational value of the data.

Q5: What does a large glucose spike after a meal mean?

A postprandial glucose spike is a normal physiological response to carbohydrate-containing meals. In non-diabetic individuals, blood glucose typically rises and returns to baseline within 2 hours. The magnitude of the spike varies significantly between individuals eating identical meals, largely due to differences in gut microbiome, insulin sensitivity, meal composition, prior exercise, and sleep quality.1 An isolated spike does not indicate a metabolic disorder. Patterns across multiple meals are more informative than individual readings.

Q6: Does exercise reliably lower glucose on a CGM?

Exercise generally improves glucose dynamics over time by increasing insulin sensitivity and facilitating glucose uptake into muscle tissue. However, the acute effect on CGM readings depends on exercise type, duration, intensity, and fasting state at the time of activity. Aerobic exercise often produces a visible glucose decrease during and after activity; high-intensity resistance training may temporarily raise glucose via stress hormone activation before it normalises. CGM data makes these responses personally visible across multiple training sessions.

Q7: Is Dexcom Stelo available without a prescription?

Yes. Dexcom Stelo received US FDA clearance as an OTC CGM for adults 18 and over who do not use insulin, making it the first CGM cleared for non-prescription use in the United States. Regulatory pathways and OTC availability vary by country; in many European markets CGMs still require a healthcare provider recommendation or prescription. Users should verify local availability and regulations.

Q8: Should I take chromium or magnesium supplements based on CGM data?

CGM data alone is not a basis for supplement decisions. Both chromium and magnesium play functional roles in normal metabolic physiology — chromium contributes to normal macronutrient metabolism and normal blood glucose levels (EFSA-approved claim), and magnesium has been studied in relation to insulin sensitivity in human RCTs.5,6 Whether supplementation is appropriate for a given individual depends on dietary intake, health status, and individual needs — factors best assessed with a qualified healthcare professional rather than based on CGM readings alone.

Frequently Asked Questions

What is a CGM and how does it work for non-diabetics?

A continuous glucose monitor (CGM) is a wearable device that measures glucose in the interstitial fluid beneath the skin via a small subcutaneous electrode. It provides real-time glucose readings every 1–15 minutes without requiring finger-stick tests. For non-diabetics, CGMs are used as educational and self-monitoring tools to observe how foods, exercise, sleep, and stress affect individual glucose dynamics — not as medical devices for clinical management.

Which CGM is best for a non-diabetic person?

The best option depends on your goals. Dexcom Stelo is the most accessible OTC option in the US without a healthcare provider. Nutrisense is well suited to individuals who want dietitian coaching alongside their data. Levels suits self-directed users comfortable with algorithmic meal scoring and independent interpretation. All three use validated sensor technology; the differences lie in support structure, price, and access pathway rather than sensor accuracy.

Is it safe to use a CGM if I do not have diabetes?

CGM devices are generally considered safe for use in healthy adults. The small subcutaneous sensor is minimally invasive. Common mild reactions include skin irritation at the sensor site. CGMs are not therapeutic devices — they do not administer any substance and do not alter physiological function. Individuals with known skin sensitivities, coagulation issues, or medical conditions should discuss suitability with a healthcare provider before use.

What does chromium contribute to in normal metabolic function?

Chromium contributes to normal macronutrient metabolism and maintenance of normal blood glucose levels — this is an EFSA-approved health claim. Chromium is an essential trace mineral involved in the normal action of insulin on target tissues. Dietary sources include whole grains, meat, and some vegetables. Supplemental chromium is available in several forms, most commonly as chromium picolinate. Evidence for supplementation benefits is most consistent in individuals with impaired glucose regulation; effects in metabolically healthy non-diabetic adults are less well established.9

Does magnesium supplementation help with blood sugar control in non-diabetics?

Magnesium plays a functional role in glucose transport and insulin receptor signalling. A double-blind RCT in non-diabetic individuals with insulin resistance found that oral magnesium supplementation reduced HOMA-IR compared to placebo.6 Meta-analyses of RCTs support a significant effect of magnesium on HOMA-IR, particularly in individuals with lower baseline magnesium status.5 EFSA-approved claims for magnesium include contributions to normal energy-yielding metabolism. Benefits are most pronounced in those with insufficient magnesium intake; routine supplementation is best assessed based on individual dietary status and health context.

References

  1. Hjort A, Iggman D, Rosqvist F. Glycaemic variability, assessed with continuous glucose monitors, is associated with diet, lifestyle and health in people without diabetes. BMJ Nutrition, Prevention & Health. 2023;6(2):174–185. View on PubMed ↗
  2. Hjort A, Iggman D, Rosqvist F. Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis. Clin Nutr. 2024 Apr;43(4):915–925. View on PubMed ↗
  3. Steil GM, Rebrin K, Hariri F, et al. Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring. Diabetes Technol Ther. 2009;11(12):749–755. View on PubMed ↗
  4. Buscemi S, Verga S, Cottone S, et al. Glycaemic variability and inflammation in subjects with metabolic syndrome. Acta Diabetol. 2009;46(1):55–61. View on PubMed ↗
  5. Veronese N, Watutantrige-Fernando S, Luchini C, et al. Effect of magnesium supplementation on glucose metabolism in people with or at-risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials. Pharmacol Res. 2016;111:272–279. View on PubMed ↗
  6. Mooren FC, Kruger K, Volker K, Golf SW, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects — a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab. 2011;13(3):281–284. View on PubMed ↗
  7. Buscemi S, Verga S, Cottone S, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. Diabet Med. 2010;27(7):823–827. View on PubMed ↗
  8. Asbaghi O, Naeini F, Ashtary-Larky D, et al. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Trace Elem Med Biol. 2020;61:126555. View on PubMed ↗
  9. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr. 2002;76(1):148–155. View on PubMed ↗
  10. Morais JBS, Severo JS, de Alencar GRR, et al. Effect of magnesium supplementation on insulin resistance in humans: A systematic review. Nutrition. 2017;38:54–60. View on PubMed ↗
Educational content only. Not medical advice. Supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional if you have a medical condition or take medication.